Xeris Biopharma Holdings (XERS) Non-Current Deffered Revenue (2020 - 2022)

Xeris Biopharma Holdings' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $6.6 million for Q3 2022.

• Quarterly Non-Current Deffered Revenue fell 2.65% year-over-year to $6.6 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $6.6 million (down 2.65% YoY) and the FY2021 annual result came in at $6.9 million, up 3.83% from the prior year.
• Non-Current Deffered Revenue was $6.6 million for Q3 2022 at Xeris Biopharma Holdings, down from $6.8 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $6.9 million in Q1 2022 and bottomed at $6.6 million in Q4 2020.
• A 3-year average of $6.8 million and a median of $6.8 million in 2021 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue grew 3.83% — and 2022, when it slipped 2.65%.
• Xeris Biopharma Holdings' Non-Current Deffered Revenue stood at $6.6 million in 2020, then rose by 3.83% to $6.9 million in 2021, then slipped by 3.46% to $6.6 million in 2022.
• Business Quant data shows XERS's Non-Current Deffered Revenue at $6.6 million in Q3 2022, $6.8 million in Q2 2022, and $6.9 million in Q1 2022.